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The sequence of the human genome together with sequence similarity analy-
ses has advanced the discovery of missing steps in the mitochondrial one-
carbon metabolism pathway. That together with the revived interest in
cancer metabolism has brought the research on one-carbon metabolism back
under the spotlight. Here, we present a brief review of recent advances in the
field of one-carbon metabolism, with a bias towards its relevance to cell
growth and proliferation in human cancers. We will address the requirements
of one-carbon metabolism for biosynthesis and the major sources to satisfy
that demand. We will also discuss some recent discoveries indicating a role of
one-carbon metabolism beyond biosynthesis. We conclude with a concise
enumeration of some fundamental questions that remain unanswered.
Introduction
The one-carbon metabolism pathway is composed of
biochemical reactions that mediate the transfer of a
one-carbon moiety (or unit) from donor to acceptor
molecules, using folate as a cofactor [1]. In mammalian
cells, serine, glycine, formate, choline, betaine, sar-
cosine and histidine are potential donors of one-
carbon units and purines, methionine and thymidylate
are potential acceptors. Mammalian cells can also
release the one-carbon unit to extracellular media as
formate or CO2. Folate cofactors are found in
different forms, from the pure or primary folate (pter-
oyl monoglutamate, vitamin B9) to derivatives with
different levels of oxidation/reduction and different
number of glutamate groups (polyglutamates). The
reduction of folates facilitates its transport across
membranes and the addition of glutamate groups
enhances its retention in cellular compartments.
One-carbon metabolism is essential to satisfy the
biosynthetic demands of highly proliferative mam-
malian cells. Examples are the rapid cell population
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expansion during embryonic development [2], T-cell
lymphocyte activation [3,4] and during rapid tumour
growth [5]. These rapidly proliferating cells require
one-carbon metabolism for the de novo synthesis of
purines and thymidylate. In contrast, as discussed
here, methionine synthesis is negligible in proliferating
cancer cells, where methionine is instead imported
from the serum at rates sufficient to satisfy the biosyn-
thetic demand.
In mammalian cells, and eukaryotes in general, one-
carbon metabolism is partitioned between reactions
taking place in the cytosol or in the mitochondria [1].
Although there is some level of isomorphism between
the cytosolic and mitochondrial pathways, there are
some differences. In this review, we summarize recent
discoveries regarding the compartmentalization of
mammalian one-carbon metabolism in the context of
cancer. The discussion will be focused around the flow
of one-carbon units rather than on folate metabolism.
For a more comprehensive review on the subject,
touching on the evolution of one-carbon metabolism,
we recommend the excellent review by Tibbetts and
Appling [1]. We will discuss the state of the art of one-
carbon metabolism in the cancer field.
Compartmentalization of one-carbon
metabolism
Mammalian cells have complementary pathways for
one-carbon metabolism in the cytosol and the mito-
chondria (Fig. 1). Serine and glycine are the major
donors of one-carbon units. Serine hydroxymethyl-
transferase (SHMT) transfers a one-carbon moiety
from serine to tetrahydrofolate (THF), forming 5,10-
methylene-THF (5,10-CH2-THF) and glycine. The
gene SHMT1 encodes the cytosolic SHMT (SHMT1)
[6], whereas SHMT2 encodes two isoforms, mitochon-
drial SHMT (SHMT2) and cytosolic/nuclear SHMT
(SHMT2a) [7]. In the mitochondria, the glycine cleav-
age system transfers a one-carbon moiety from glycine
to 5,10-CH2-THF, releasing CO2 and ammonia. The
glycine cleavage system is a complex of the T-, L-, P-
and H-protein. Protein P has glycine decarboxylase
activity and it is encoded by GLDC. Protein T has
aminomethyltransferase activity and it is encoded by
AMT. Protein L has dihydrolipoyl dehydrogenase
activity and it is coded by DLD. Finally, protein H,
encoded by GCSH, shuttles the methylamine group of
glycine from the P to the T protein.
5,10-CH2-THF is converted back to THF through
different folate cycles, depending on the final one-
carbon acceptor. On one folate cycle, the bifunctional
5,10-methylene-tetrahydrofolate dehydrogenase/5,10-
methylene-tetrahydrofolate cyclohydrolase (MTHFD)
enzyme converts 5,10-CH2-THF to 10-formyl-THF
(10-CHO-THF) (Fig. 1 FOR cycle). There are two
homologous genes encoding bifunctional MTHFDs
that localize to the mitochondria, MTHFD2 and
MTHFD2L encoding MTHFD2 and MTHFD2L
respectively. MTHFD2 is expressed in highly prolifera-
tive cells, during embryonic development and in cancer
cells [8–11]. In vitro biochemical studies indicate that
MTHFD2 activity is predominantly NAD+-dependent
[12]. MTHFD2L is expressed in adult tissues and
in vitro biochemical studies indicate that it has similar
NAD+/NADP+-dependent activities [13,14]. 10-CHO-
THF is converted back to THF via either reverse
10-CHO-THF synthase (FTHFS), releasing the one-
carbon as formate, or via 10-CHO-THF dehydroge-
nase (FTHFD), releasing the one-carbon as CO2.
There is a mitochondrial FTHFS encoded by
MTHFD1L [15] and cytosolic/mitochondrial FTHFDs
encoded by ALDH1L1/ALDH1L2 respectively [16,17].
In the cytosol, a single gene product from the
MTHFD1 gene encodes a trifunctional enzyme with
MTHFD and FTHFS activities [18]. A function of
MTHFD1 is to recapture the formate released by
mitochondrial MTHFD1L to form cytosolic 10-CHO-
THF, which is then used in two different steps of
purine synthesis, recovering back THF [1].
On another folate cycle, thymidylate synthase (TS)
transfers a one-carbon from 5,10-CH2-THF to dUMP,
forming thymidylate (dTMP) and dihydrofolate
(DHF) (Fig. 1, dTMP cycle). DHF reductase (DHFR)
converts DHF back to THF. Thymidylate synthesis
takes place in both the mitochondria and the nucleus
(Fig. 1), supporting the synthesis of mitochondrial and
cytosolic DNA respectively. A single gene, TYMS,
encodes a gene product that localizes to both the cyto-
sol and the nucleus and it is responsible for the TS
activity in these compartments. The product of the
gene DHFR is responsible for the cytosolic/nuclear
DHFR activity [19]. There is a second gene, DHFRL1,
that encodes a protein that localizes to the mitochon-
dria and it is responsible for the DHFR activity in this
compartment [20]. Finally, purine and methionine
synthesis are localized in the cytosol.
One-carbon metabolism is essential
for development
The metabolism of cancer resembles the metabolism of
growth and development in many aspects [21]. With
this perspective in mind, we can learn about the essen-
tiality of one-carbon metabolism enzymes by studying
their requirements during embryonic development.
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Homozygous Mthfd2 knockout mice die in utero.
Homozygous deletion of either Mthfd2 [22], Mthfd1l
[2], or Amt [23] causes embryonic lethality and neural
tube defects in mice. However, knock-down experi-
ments in cancer cells in vitro have resulted in conflict-
ing outcomes. MTHFD1L or MTHFD2 knock-down
inhibits growth and viability of the nonmetastatic
breast cancer cell line MCF7 [24]. In contrast,
MTHFD2 knock-down does not impair the growth
and viability of the highly metastatic breast cancer
lines MDA-MB-231 and BT-549 [24,25], although it
affects their invasive potential. It is possible that
Fig. 1. Compartmentalization of one-carbon metabolism in mammalian cells. Different compartments are highlighted with different
background colours. Metabolic enzymes are enclosed in boxes. Arrows indicated the flow of one-carbon units based on current evidence.
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different cancer types have different degrees of depen-
dency on these mitochondrial one-carbon metabolism
enzymes for proliferation. For example, we cannot
exclude that in some cancer cells, the cytosolic
pathway is able to compensate for the inhibition of
the mitochondrial pathway. Finally, it cannot be dis-
counted that the embryonic lethality and neural tube
defects observed in mice deficient in mitochondrial
one-carbon metabolism genes are not linked to cell
growth but to tissue remodelling during development.
Serine is the main donor of one-
carbon units
Early investigations interrogating the nutrient require-
ments of activated human lymphocytes demonstrated
that serine is the main donor of one-carbon units in
proliferating normal cells [3,4]. Serine deprivation
arrests activated lymphocytes in the G1 phase of the
cell cycle, and growth resumes upon addition of serine
[3]. Other potential sources of one-carbon units such
as glycine, choline and histidine do not rescue growth,
and formate only partially rescues growth upon serine
starvation [4].
The discovery of signalling pathways regulating this
cell cycle arrest had to wait until the advent of molec-
ular biology research and the renewed interest in can-
cer metabolism. In cancer cells, cell cycle arrest due to
serine starvation is p53-dependent [26]. Cancer cells
lacking p53 do not arrest upon serine starvation.
Instead they die due to a mismatch between the supply
and demand of glycine [26]. As observed in activated
lymphocytes, glycine does not rescue serine starvation
of cancer cells. In contrast, addition of exogenous
glycine inhibits growth [27]. Mechanistically, in the
absence of extracellular serine, the activity of SHMT is
reverted from glycine producing to glycine consuming,
from production to consumption of one-carbon units.
As a consequence, there is a depletion of the one-
carbon unit pool and inhibition of purine synthesis.
Addition of formate rescues growth, demonstrating the
inhibition of purine synthesis as the mechanism of
growth inhibition [27]. There was an earlier report sug-
gesting that glycine supports rapid proliferation in can-
cer cells [28]. However, those observations are most
likely an artefact of serine depletion during the course
of the experiments, which affects mostly the results for
rapidly proliferating cells.
In mammalian cells, serine can be taken up from the
extracellular medium or it can be synthesized from glu-
cose. In vitro studies indicate that proliferating cells
use both sources but with a higher flux of serine
uptake relative to serine synthesis from glucose [26,29].
In cancer cells, serine is actually imported at a rate
that exceeds the serine demand and the excess serine is
converted to glycine [30]. However, some cancer cells
have amplifications of the PHGDH gene [31,32],
encoding the enzyme 3-phosphoglycerate dehydroge-
nase, the first step in the branching point from glycoly-
sis to serine synthesis. Examples include the breast
cancer cell lines MDA-MB-468, BT-20 and HCC70
[31] and the melanoma cell lines WM266-3, Malme
and SK28 [32]. Cancer cells with PHGDH amplifica-
tions have higher levels of the gene product and a
higher rate of serine synthesis from glucose. Down-
regulation of PHGDH expression inhibits the growth
of cancer cells with PHGDH amplifications but not of
cells with normal PHGDH copy number. Why cancer
cells with high PHGDH expression are dependent on
the PHGDH metabolic activity remains an open ques-
tion. Cancer cells could also import serine from the
extracellular media [28,33], suggesting that the synthe-
sis of the pathway end product, serine, is not the
selected phenotype. The serine synthesis pathway con-
tains a NAD+ dehydrogenase step (catalysed by
PHGDH), suggesting that this pathway could con-
tribute NADH generation. However, as the rate of ser-
ine synthesis is low relative to the rate of glycolysis,
even in cells with high PHGDH expression, glycolysis
is the major source of NADH generation in the cyto-
sol. The serine synthesis pathway also contains a
transaminase step catalysed by phosphoserine amino-
transferase (PSAT, encoded by PSAT1 in humans),
converting glutamate to a-ketoglutarate. In cancer cells
with high PHGDH expression, the generation of a-
ketoglutarate from the serine synthesis pathway is sig-
nificant when compared with other pathways [31].
These data suggest that the selective advantage of high
PHGDH expression is more likely linked to the contri-
bution of serine synthesis to the glutamate/a-ketoglu-
tarate balance.
Relative contribution of cytosolic and
mitochondrial pathways
Isotope tracing is the main tool to determine the direc-
tion of metabolic fluxes and to quantify the contribu-
tion of different pathways to the production of the
same product. In ground-breaking work, Appling’s
laboratory investigated the incorporation of medium
[3-13C1]-serine into yeast intracellular metabolites using
NMR spectroscopy [34]. They observed significant
amounts of intracellular [2-13C1]-glycine that could
only be obtained by the reverse activity of mitochon-
drial glycine cleavage together with [13C1]-5,10-CH2-
THF derived from mitochondrial SHMT activity.
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Later, studies switched to [2,3,3-2H3]-serine to tease
out the relative contribution of the cytosolic and mito-
chondrial pathways. In a nutshell, the generation of
cytosolic 5,10-CH2-THF can be done using the cytoso-
lic or mitochondrial pathways. The cytosolic route is
basically one step catalysed by SHMT1 and it pro-
duces [2H2]-5,10-CH2-THF (M + 2) (Fig. 2, black
arrows). In contrast, the mitochondrial route requires
a dehydrogenase step where one deuterium (2H) is
released, resulting in [2H1]-5,10-CH2-THF (M + 1)
(Fig. 2, green arrows). The relative abundance of
M + 1/M + 2 5,10-CH2-THF is then reflected on the
relative abundance of M + 1/M + 2 thymidylate and
of M + 1/M + 2 methionine, which can both be quan-
tified using mass spectrometry. In mouse embryonic
fibroblasts, about 85% of deuterated methionine is
M + 1 and it goes down to about 23% in Mthfd2 null
cells [15]. In breast cancer MCF7 cells, about 97.8%
of deuterated methionine and about 93.3% thymidy-
late are M + 1 [35]. These data strongly support the
mitochondrial pathways as the main route of forma-
tion of cytosolic one-carbon units.
More recently, a reported assay has been developed
exploiting the discovery of neomorphic mutations in
IDH1 and IDH2 [36]. The cancer genome sequencing
projects uncovered IDH1 and IDH2 mutations in the
context of human cancers, including acute myeloid
leukaemias (AML) [37] and gliomas [38,39]. These
mutations were found at specific amino acid residues,
R132 in IDH1 or R140 and R172 in IDH2, suggest-
ing some functional relevance. Indeed, follow-up
biochemical studies demonstrated that these muta-
tions result in neomorphic IDH enzymes catalysing
the conversion of a-ketoglutarate to (D)2-hydroxyglu-
tarate (2HG) with the concomitant transfer of a
hydrogen atom from NADPH to 2HG [40,41]. In
IDH1/2 wild-type cells, 2HG is found at very low
levels. In contrast, expression of the neomorphic
IDH1/2 mutant enzymes results in high 2HG concen-
trations. As IDH1 localizes to the cytosol and IDH2
to the mitochondria, cells transfected with IDH1 or
IDH2 mutant enzymes can be utilized to trace 2H
from a 2H-labelled nutrient to NADPH in the cytoso-
lic and mitochondrial compartments respectively
(Fig. 2, blue boxes). Specifically, in cells transfected
with IDH1 mutant enzyme, the 2HG M + 1 fraction
serves as a readout of the SHMT/MTHFD activity in
the cytosol, and in cells transfected with IDH2
mutant enzyme, the 2HG M + 1 fraction serves as a
readout of the SHMT/MTHFD activity in the
mitochondria. Using this reported assay, it has been
confirmed that in cancer cells, serine is the major
one-carbon donor and the SHMT/MTHFD activity is
mostly mitochondrial [36].
Fig. 2. [2,3,3-2H3]-serine tracing to determine the relative contribution of cytosolic (black lines) and mitochondrial (green lines) one-carbon
metabolism pathways. The black empty circles represent carbon atoms and the red-filled circles represent 2H atoms. Metabolic enzymes
are enclosed in boxes and are highlighted with a blue background for mutant IDH1/2 enzymes.
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The predominant use of the mitochondrial SHMT/
MTHFD pathway in proliferating cancer cells is fur-
ther corroborated by protein expression profiles. Using
proteomic data reported for the NCI panel of 60 can-
cer cell lines [42], we have quantified the relative abun-
dance of the different proteins in the cytosolic and
mitochondrial one-carbon metabolism pathways
(Fig. 3). SHMT2 is by far the most abundant protein
in all cell lines. At an intermediate relative level of
expression, we find MTHFD2, ALDH1L2, GLDC and
GCSH, all localizing to the mitochondria. In contrast,
the expression of the cytosolic SHMT1 and MTHFD1
proteins is relatively small. The protein expression
analysis also reveals that some cell lines do express rel-
atively high levels of the glycine cleavage components
GLDC and GCSH. Future research should determine
whether glycine substitutes for serine as a one-carbon
donor in these cancer cell lines.
The pattern of expression is different in somatic tis-
sues and it depends on the tissue type [14]. In the kid-
ney and liver of adult mice, Mthfd1 gene expression is
the highest, with negligible expression of the mitochon-
drial pathway genes Mthfd2, Mthfd2l and Mthfd1l. In
contrast, in the brain and the spleen, Mthfd1l exhibits
levels of expression similar or higher to Mthfd1. While
it is not straightforward to extrapolate from the
expression of metabolic enzyme genes to actual meta-
bolic fluxes, these data indicate that the cytosolic and
mitochondrial one-carbon metabolism pathways are
used differently in nonproliferating somatic tissues and
that there are differences across tissue types.
Roles of glycine cleavage
As we have just discussed, most of the reported data
indicate serine as the main donor of one-carbon units
in cancer cells. Experiments culturing baby mouse kid-
ney cells (iBMK) [43] or HCT116 lung cancer cells in
culture medium with 13C-labelled glycine have shown
that glycine cleavage does not contribute to the gener-
ation of one-carbon units in these cells. Yet, there is
also evidence pointing to a role for the glycine
cleavage system (GCS) in cancer, albeit not as a major
one-carbon donor. Overexpression of GLDC, the
enzyme catalysing the first glycine decarboxylase step
of the GCS, drives tumour formation in lung adeno-
carcinoma [44]. Knock-down of GLDC in lung adeno-
carcinoma-derived A549 cells results in significant
changes in the levels of several metabolites and inhi-
bits proliferation. Among the altered metabolites, sar-
cosine levels significantly decreased upon GLDC
knock-down in A549 cells. In turn, supplementation
with 10 lM sarcosine was sufficient to rescue the
growth inhibition caused by GLDC knock-down. It
remains unclear how GLDC knock-down results in
reduced sarcosine levels. In human cells, glycine and
sarcosine can be interconverted by sarcosine dehydro-
genase and glycine N-methyltransferase. Knock-down
of GLDC results in increased levels of glycine [44], in
principle favouring the formation of sarcosine.
Instead, a decrease of sarcosine levels was observed
[44]. However, given that the GLDC knock-down
leads to several metabolic changes, there could be
other rearrangements favouring a decrease in sarcosine
levels.
In glioblastoma cells with high SHMT2 activity,
glycine cleavage protects cells from toxicity associated
with high glycine levels [45]. Knock-down of GLDC,
the first glycine decarboxylase step of the GCS,
results in loss of viability and breakdown of neuro-
spheres formed by gliobastoma-derived cell lines. The
loss of viability was tracked down to the toxic effects
Fig. 3. Expression of one-carbon
metabolism proteins across a panel of
tumour-derived cell lines, based on
proteomic data previously reported [42].
The bars represent the sum of intensities
of peptides mapping to the corresponding
protein relative to the sum of intensities of
all detected peptides. The levels of
MTHFD1L and ALDH1L1 were below
detection limit in all samples.
3700 The FEBS Journal 283 (2016) 3695–3704 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
The flux of one-carbon in cancer cells J. Meiser and A. Vazquez
of the glycine metabolism by-products. Mechanisti-
cally, the presence of an active GCS prevents the
accumulation of high glycine levels. Inhibition of the
GCS leads to increased glycine levels favouring the
occurrence of less efficient reactions that do not take
place at a significant rate at low glycine levels.
Knock-down of GLDC or glycine overload results in
an increase of aminoacetone and methylglyoxal levels
in a glycine C-acetyltransferase (GCAT)-dependent
manner [45]. Taken together this evidence points to a
protective role of the GCS in cells with high SHMT2
activity.
Interactions with methylation
metabolism
One-carbon metabolism intersects with methylation
metabolism (Fig. 1, MET and methylation cycles). The
activity of 5-methyl-THF (5-CH3-THF) reductase
(MTHFR) converts 5,10-CH2-THF to 5-CH3-THF. The
methionine synthase (MS) then transfers a one-carbon
unit from 5-CH3-THF to homocysteine forming
methionine, the source of methyl groups in mammalian
cells (Fig. 1, methylation cycle). In mouse embryonic
fibroblasts cultured in medium containing [2,3,3-2H3]-
serine only, about 4% of methionine is deuterated [15],
indicating extracellular methionine as the main source
of intracellular methionine. Tracing experiments with
13C-labelled serine or methionine have shown that extra-
cellular methionine is the main source of methionine in
proliferating cancer cells as well [29,33,46,47]. Taken
together this evidence indicates that in proliferating
mammalian cells and in cancer cells, one-carbon meta-
bolism has a negligible contribution to the generation of
methionine.
However, to donate the methyl group, methionine
needs to be first converted to S-adenosylmethionine
(SAM), the universal methyl donor in methylation
reactions. SAM is synthesized by the methionine
adenosyltransferase (MAT)-dependent ligation of a
methionine molecule and an ATP molecule. The
requirement of an ATP molecule as chemical group
(not an energy currency) for the synthesis of SAM
prompted Maddocks et al. [33] to investigate methyla-
tion metabolism in the context of serine starvation.
As discussed above, in cancer cells, serine is the major
source of one-carbon units for purine synthesis, and
serine deprivation results in a significant drop in pur-
ine levels. Maddocks et al. were able to show that the
inhibition of purine synthesis by serine deprivation
significantly impairs RNA/DNA methylation by
reducing the availability of ATP for the synthesis of
SAM.
Nonbiosynthetic roles
The evidence reviewed so far demonstrates the require-
ment of one-carbon metabolism for de novo synthesis
of purines and thymidylate. However, recent data sug-
gest that one-carbon metabolism has roles beyond
biosynthesis. First, in proliferating cancer cells, the
generation of one-carbon units from serine exceeds the
one-carbon demand for purine synthesis [29]. Second,
there are reactions in one-carbon metabolism that can
generate ATP and NADPH, potentially contributing
to the energy and antioxidant demands of proliferating
cells.
The investigation of in silico models of human cell
metabolism predicts that serine catabolism can gener-
ate ATP via the activity of reverse FTHFS (MTHFD1
or MTHFD1L) [48] (see Fig. 1). There is currently no
direct experimental evidence for a net production of
ATP by the overall activity of cytosolic and mitochon-
drial reverse FTHFS activity. Yet, treatment of cancer
cells with the antifolate methotrexate results in energy
stress, characterized by an increase of the AMP/ATP
ratio and activation of AMP kinase (AMPK) [9], pro-
viding some indirect evidence.
The investigation of in silico models of human cell
metabolism also predicts that serine catabolism can
generate NADPH via the activity of cytosolic and
mitochondrial MTHFD and FTHFD (see Fig. 2)
[29,43,48]. This prediction is corroborated by the
experimental quantification of NADPH production
fluxes in cancer cells, albeit with some differences in
the differential utilization of the cytosolic and mito-
chondrial pathways. In immortalized baby mouse
kidney cells (iBMK) cultured in [2,3,3-2H3]-serine,
there is a significant labelling of NADPH from media
[2,3,3-2H3]-serine [43]. Furthermore, Mthfd1 knock-
down drastically reduced the NADPH labelling from
serine, suggesting that NADPH production was from
the cytosolic pathway.
Studies using the IDH1/IDH2 reporter assays pro-
vide additional evidence for NADPH production from
serine catabolism. As IDH1 and IDH2 are predomi-
nantly NADP+-dependent dehydrogenases, the frac-
tion of 2H-2HG in cells cultured with [2,3,3-2H3]-serine
quantifies the relative contribution of serine one-carbon
catabolism to the generation of NADPH (Fig. 2, blue
boxes). Furthermore, using cells transfected either with
mutant IDH1 or IDH2, it is possible to tease out the
relative contribution to the cytosolic and mitochondrial
NADPH pools. In experiments done with H1299 and
A549 lung cancer cell lines, there was a significant
labelling of 2HG from [2,3,3-2H3]-serine only in cells
transfected with an IDH2-encoding plasmid, indicating
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that in these cells serine catabolism contributes to
NADPH generation in the mitochondria.
The observed differences between NADPH produc-
tion in the cytosol of kidney cells versus NADPH
production in the mitochondria of proliferating cancer
cells are consistent with the protein expression differ-
ences highlighted above. In cancer cells, there is a pre-
dominant expression of the mitochondrial pathway
proteins (particularly SHMT2, Fig. 3), while in the
kidney and liver of mice, MTHFD1 is highly expressed
compared to all other tissues and all other one-carbon
metabolism proteins.
The potential contribution of one-carbon metabolism
to NAPH generation is consistent with the observation
that NRF2, a master transcription factor of antioxidant
response, controls the expression of genes in one-carbon
metabolism in nonsmall cell lung cancer (NSCLC) cells
with high NRF2 expression (e.g., A549) [49]. In mam-
malian cells, glutathione (GSH) oxidation/reduction
coupled to NADPH reduction/oxidation is a major
pathway for ROS detoxification. One-carbon metabo-
lism can contribute ROS detoxification in two ways.
The transcription factor NRF2 regulates the expression
of several genes involved in ROS detoxification. The
fact that it also regulates the expression of genes in the
serine synthesis pathway (PHGDH, PSAT1) and one-
carbon metabolism (SHMT2) supports these roles. It is
worth noticing that this regulation is indirect, via the
activity of ATF4, a master regulator of cell response to
amino acid starvation.
Outlook
The discovery of missing steps in the mitochondrial
one-carbon metabolism pathway together with the
revived interest on cancer metabolism has brought one-
carbon metabolism back under the spotlight. Recent
studies have significantly advanced our understanding
of the differential utilization of cytosolic and mitochon-
drial pathways by cancer cells. In turn, this body of
work has left open some fundamental questions.
There is evidence indicating that that one-carbon
metabolism contributes to NADPH generation [36,43].
Yet, it is not clear how much of that contribution is a
by-product of unavoidable dehydrogenase steps in
biosynthetic pathways combined with a limited NADH
oxidation capacity or a bona fide NADPH generation
to fulfil both the biosynthetic and antioxidant
NADPH demand.
Theoretical models suggest that the reverse activity
of cytosolic or mitochondrial FTHFS can produce
ATP with concomitant one-carbon release as formate
[48]. If this theoretical prediction was proven true, it
would imply serine one-carbon catabolism as a third
pathway for energy generation in mammalian cells,
besides the established glycolysis and mitochondrial
oxidative phosphorylation.
We have a limited understanding about the role of
glycine cleavage in cancer. There is some evidence sup-
porting a tumour-promoting role in the formation of
lung adenocarcinoma [44] and a protective role in
glioblastomas with high SHMT2 expression [45]. How-
ever, it is not clear whether these two observations are
connected and what their relevance is in other cancer
types. Overall, we currently have a poor understanding
of mitochondrial glycine metabolism in cancer.
Finally, it is established that mitochondrial one-
carbon metabolism is the source of cytosolic one-carbon
units in proliferating yeast [34,50], mammalian [1,3,4]
and cancer cells [36]. Yet, we do not understand what
is the evolutionary advantage of this choice. Purine
synthesis is the major demand of one-carbon units in
proliferating cells and all the purine synthesis enzymes
are localized in the cytosol. The key question is why
one-carbon metabolism uses the mitochondrial instead
of the cytosolic one-carbon metabolism pathway. It
cannot be excluded that the answer to some of the pre-
vious questions will shed light on the evolutionary
advantage of a mitochondrial route for the generation
of one-carbon units.
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